Product Program year 2022 Source: CMS Open Payments

Epaned

Drug pediatric hypertension

NDC 52652-4001-1

Open in the dashboard

General payments

$50,890

202 payments

Research payments

$0

0 payments

Through program year 2022, $50,890 in general payments and $0 in research payments were reported against Epaned (pediatric hypertension).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2022 General $144 9
2021 General $48,279 57
2020 General $1,610 88
2019 General $857 48

Breakdown

Who paid General payments · program years 2019–2022
  1. CutisPharma, Inc. $49,451 122 payments
  2. Silvergate Pharmaceuticals, Inc. $1,438 80 payments
Top recipients General payments · program year 2022
  1. Brandon Morrical Pediatric Cardiology · Chattanooga, TN $16 11% · 1 payment
  2. Wesley Davis Pediatric Cardiology · Chattanooga, TN $16 11% · 1 payment
  3. James Raulston Birmingham, AL $16 11% · 1 payment
  4. Christine Gale Gynecology · Knoxville, TN $16 11% · 1 payment
  5. Mihail Subtirelu Pediatric Nephrology · Knoxville, TN $16 11% · 1 payment

The top 5 of 9 recipients; each share is of general payments naming this product in 2022.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2022
  1. Pediatric Cardiology Pediatrics $33 26% · 2 practitioners
  2. Pediatric Nephrology Pediatrics $32 25% · 2 practitioners
  3. Gynecology Obstetrics & Gynecology $16 12% · 1 practitioner
  4. Nurse Practitioner, Family Nurse Practitioner $16 12% · 1 practitioner
  5. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $16 12% · 1 practitioner

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2022
  1. Tennessee $144 100% · 9 recipients

Each share is of general payments naming this product in 2022 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

12

Prescriptions dispensed, refills included

Drug cost

$14,708

Paid at the pharmacy, in all

Prescribers

1

With 11 or more claims of it

Medicare Part D drugs matched to Epaned, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Epaned Enalapril Maleate Same name 1 12 $14,708

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

1 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Victor Jackson Internal Medicine LA 12 $14,708 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

202 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record